Physician profile
Robert Allen Comp
NPI 1588617724
$8,917.85
in general payments reported to CMS, 2019-2025
44 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,417 · 2020: $367 · 2021: $846 · 2022: $1,883 · 2023: $1,095 · 2024: $1,518 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,405.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,443.81 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,428.76 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Genzyme Corporation | $761.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $731.21 | 2019-2025 | Ofev |
| Insmed, INC. | $486.61 | 2019-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $366.26 | 2019-2025 | Dupixent |
| Pulmonx Corporation | $275.72 | 2023-2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Baxter Healthcare | $257.58 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
| Genentech USA, INC. | $250.61 | 2019-2023 | Xolair |
| Inari Medical, INC. | $242.75 | 2022 | |
| Mylan Specialty L.P. | $225.01 | 2019-2024 | Yupelri |
| Amgen INC. | $219.31 | 2021-2025 | Tezspire |
| Electromed, INC. | $218.97 | 2021-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $188.39 | 2022-2025 | Glassia, Hyqvia |
| Philips North America LLC | $174.73 | 2019-2025 | Encore |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $157.03 | 2019-2023 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $132.61 | 2019-2025 | Zerbaxa, Recarbrio |
| Sunovion Pharmaceuticals INC. | $132.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $119.46 | 2021-2024 | |
| United Therapeutics Corporation | $118.51 | 2021-2022 | |
| Harmony Biosciences LLC | $112.58 | 2022-2023 | Wakix |
| Intuitive Surgical, INC. | $99.40 | 2025 | |
| Advanced Respiratory, INC | $71.22 | 2019-2021 | |
| Covis Pharma Gmbh | $69.97 | 2021-2022 | |
| Abbott Laboratories | $60.38 | 2024 | Aveir |
| Verona Pharma, INC. | $56.98 | 2025 | Ohtuvayre |
| Inogen, INC. | $53.13 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Csl Behring | $48.71 | 2019-2022 | |
| Shionogi INC | $44.96 | 2021-2022 | |
| Abbvie INC. | $44.12 | 2022-2025 | |
| Phadia US INC. | $37.32 | 2023-2024 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $34.92 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $33.83 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $33.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $24.43 | 2019 | |
| Grifols USA, LLC | $24.34 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.79 | 2024 | |
| Mayne Pharma Commercial LLC | $20.04 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.46 | 2021 | |
| Circassia INC. | $16.43 | 2019 | |
| Gilead Sciences, INC. | $16.35 | 2023 | Veklury |
| Pfizer INC. | $15.12 | 2023 | |
| Biogen, INC. | $14.74 | 2023 | Spinraza |
| Astellas Pharma US INC | $13.67 | 2025 | Cresemba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Comp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.